Lycia Therapeutics’ Post

Our Co-Founders Mark Feitelson, Ph.D., CSO, Alla Arzumanyan, Ph.D., CDO, and Ira Spector, Ph.D., CEO teamed up to discuss “The promise of therapeutics from molecules within our body” in this Drug Target Review article. Learn more about how endogenous compounds have the power to treat the pathologies of many #immunological conditions. Check it out here: https://bit.ly/45bz5aH

The Special Issue of Prof. Smaragdi Antonopoulou "New Insights into Platelet- Activating Factor" has been published in #FBLjournal at https://lnkd.in/dGh3wa4U This Special Issue aims to integrate current knowledge regarding the functions of PAF in an attempt to determine novel therapeutics that most likely target PAF in conjunction with various other inflammatory mediators. Welcome to reading and contributing! #PAF_and_diet #PAF_oxidized_phospholipids_and_plasmalogens_in_inflammation #The_importance_of_PAF_in_angiogenesis #The_role_of_AF_in_immunopathology #PAF_and_cancer #PAF_and_CNS_disorders #PAF_and_COVID-19 #PAF_and_allergies #PAF_and_cardiovascular_diseases #PAF_and_gut_microbiota #PAF_inhibitors #PAF_as_a_therapeutic_target

I'm thrilled to share a glimpse into the compelling BBC documentary that has featured me and my team "Race Against Resistance: The Life and Death Struggle to Save Antibiotics," produced by @BBCStoryWorks. At Adaptive Phage Therapeutics, our unwavering commitment is to build a robust/comprehensive phage bank that directly confronts the challenge of antibiotic-resistant and hard-to-treat bacterial infections. Presently, these phages are actively engaged in three ongoing clinical trials—targeting diabetic foot infections (DFI), prosthetic joint infections (PJI), and cystic fibrosis (CF) lung infections. As a dedicated phage hunter, my journey is one of continuous exploration, driven by the quest for novel bacteriophage discoveries. This time, the path led to a unique adventure at the Baltimore Zoo. Amidst the presence of extraordinary animals, including the majestic giraffe, powerful rhino, swift cheetah, charming penguin, and countless more, I had the privilege of collecting environmental and fecal samples. Beyond the excitement of bacteriophage hunting, this experience holds profound significance. Our endeavors extend beyond the confines of laboratories, unlocking a realm of potential within the environments of endangered animals. In this treasure trove of biodiversity, we uncover insights that hold promise for saving lives—both theirs and ours. The intricate dance between bacteriophages and bacteria presents a gateway to pioneering solutions against antibiotic-resistant infections. Each time we gather a sample, we learn more about how nature works. This helps us understand the potential these phages hold for human health. This pursuit resonates with the urgency of conservation for exotic species, and it emphasizes the profound impact that biodiversity has on the trajectory of medical progress.  As we journey onward, the beacon of phage therapy, a potential vanguard of modern healthcare, illuminates a path toward revolutionary possibilities. #PhageHunting #Bacteriophages #ExoticSpecies #Biodiversity #Conservation #Innovation #HealthcareRevolution

In starting Quotient Therapeutics two years ago, we asked the question: what if the trillions of cellular genetic variations inside us hold the answers to cure, prevent, or reverse disease? We've built a powerful platform and incredible team to translate our genetic discoveries into drug discoveries. Exciting day today and the first step of many on an incredible journey to pioneer the use of #SomaticGenomics and uncover endless possibilities.  https://lnkd.in/exbfAkru

Meet the Conigen Experts Have questions about how advanced proteins can be used as antigens or immunogens? Looking for soluble dimeric proteins to develop deeper insights into your research? Wondering how your specific membrane proteins can be generated as an immunogen?   Meet the Conigen team of experts at AAI booth #337 and get insights into the latest strategies empowering translational research and drug discovery. Let's push the boundaries of research together! https://lnkd.in/eyZgGVwu   #AAI2024 #Immunology #InnovateWithConigen #AdvancedProteins

📣 Our scientific collaborator, Grey Wolf Therapeutics, recently showcased an insightful poster at #ASCO2024 in Chicago! The poster details a clinical study on immunopeptidome modulation following the administration of the ERAP1 inhibitor GRWD5769. 🧪Discover how our #TrueDiscovery® and #TrueSignature® platforms played a pivotal role in this research, enabling Grey Wolf to perform a comprehensive, unbiased, and targeted analysis of the immunopeptidome. This study continues to contribute in determining the recommended dose of GRWD5769 for the phase II clinical trial. 💊 📥 Download the poster now to dive into the details of this innovative study! https://lnkd.in/eNE9xmPH #MassSpectrometry #Proteomics #Immunopeptidomics #DrugDevlopment

Congratulations to Forward Therapeutics, Inc. on their Series A funding 🎉🎉 Toufike Kanouni, CEO, said that the team is grateful for the support from investors who "recognize the potential of [their] novel therapies to impact the lives of millions of people living with chronic immunological and inflammatory conditions." There are 80 different autoimmune diseases that we are currently aware of. More well-known ones include diabetes, lupus, MS, but others are rare and harder to diagnose. Most of these diseases have no cure, and some require lifelong treatment to ease symptoms. Collectively, these diseases affect more than 24 million people across the US alone. Through creating impactful immunology drugs, Forward Therapeutics, Inc.'s main aim is to "promote healing and restore quality of life," says Ewan Taylor, the team's CSO. Congratulations 💜 #HealthTech #BioTech #DrugDiscovery

LucidQuest Views >>> How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space. #Casestudies #casestudy Comment below! >>> lqventures.com